Sol Gel Technologies (NASDAQ:SLGL) released its earnings results on Tuesday. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.02), Fidelity Earnings reports. Sol Gel Technologies had a negative net margin of 223.99% and a negative return on equity of 71.98%.
SLGL stock opened at $7.23 on Wednesday. Sol Gel Technologies has a 52 week low of $5.00 and a 52 week high of $21.00. The company has a fifty day simple moving average of $9.81 and a two-hundred day simple moving average of $9.82. The firm has a market capitalization of $141.20 million, a P/E ratio of -3.10 and a beta of 1.51.
Several equities analysts have recently commented on the company. Raymond James boosted their price objective on Sol Gel Technologies from $21.00 to $23.00 and gave the company a “strong-buy” rating in a research report on Monday, December 30th. Jefferies Financial Group increased their price objective on shares of Sol Gel Technologies from $14.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Zacks Investment Research raised Sol Gel Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. ValuEngine upgraded Sol Gel Technologies from a “sell” rating to a “hold” rating in a research report on Friday, March 13th. Finally, HC Wainwright increased their price target on Sol Gel Technologies from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $23.00.
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Featured Article: What is the QQQ ETF?
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.